|Articles|November 17, 2022
Scalable rubella production in scale-X™ bioreactor with MRC-5 cells (Nov 2022)
Author(s)Univercells Technologies
This application note demonstrates the successful transfer, optimization and scale-up of the Rubella vaccine manufacturing process from static flasks to scale-X™ bioreactors.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Orion and Abzena Collaboration Highlights Integrated Antibody Manufacturing Advances
2
BioPharm Weekly News Roundup—Week of Oct. 20, 2025
3
SK pharmteco Invests in California Site to Overcome Peptide Purification Bottlenecks
4
Ask the Expert: Commenting on Draft Regulations
5
